# Bioequivalence of Nomegestrol Acetate (NOMAC) and Estradiol (E2) in Commercial Versus Phase 3 Pivotal Clinical Batches of NOMAC-E2 Tablets (P06328)

> **NCT01345786** · PHASE1 · COMPLETED · sponsor: **Organon and Co** · enrollment: 158 (actual)

## Conditions studied

- Healthy Postmenopausal Females

## Interventions

- **DRUG:** Commercial NOMAC-E2
- **DRUG:** Phase 3 NOMAC-E2 "Batch A"
- **DRUG:** Phase 3 NOMAC-E2 "Batch B"

## Key facts

- **NCT ID:** NCT01345786
- **Lead sponsor:** Organon and Co
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2010-06
- **Final completion:** 2010-06
- **Target enrollment:** 158 (ACTUAL)
- **Last updated:** 2022-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01345786

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01345786, "Bioequivalence of Nomegestrol Acetate (NOMAC) and Estradiol (E2) in Commercial Versus Phase 3 Pivotal Clinical Batches of NOMAC-E2 Tablets (P06328)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01345786. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*